COMMUNIQUÉS West-GlobeNewswire

Phathom Pharmaceuticals Provides Update on FDA Litigation
26/10/2026
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
NTG Nordic Transport Group A/S - Upgrade of guidance for the full year 2026
26/10/2026
Company announcement no. 41 – 26 26 October 2026 NTG Nordic Transport Group A/S - Upgrade of guidance for the full year 2026 Based on preliminary financial results for the third quarter of 2026, NTG expects adjusted [...]
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
26/10/2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS gains alongside [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
26/10/2026
COPENHAGEN, Denmark, October 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
26/10/2026
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase [...]
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
26/10/2026
TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile [...]
A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
26/10/2026
Ad hoc announcement pursuant to Art. 53 LR In a Phase 2 study in pediatric insomnia disorder, in addition to marked improvements in sleep measures, daridorexant 50 mg showed an unexpected pattern of improvement in [...]
DXS International Plc (AQSE: DXSP): Notice of AGM
26/10/2026
26 October 2026 DXS INTERNATIONAL PLC (AQSE: DXSP) Notice of AGM DXS International plc ( AQSE: DXSP ), the UK healthcare technology provider, announces that it has published its Notice of its Annual General Meeting (“ [...]
TME Pharma améliore sa visibilité financière en prolongeant l'échéance de sa dette jusqu'en juin 2028
26/10/2026
TME Pharma améliore sa visibilité financière en prolongeant l'échéance de sa dette jusqu'en juin 2028 Visibilité financière prolongée jusqu'au deuxième trimestre 2028 Tous les détenteurs de dette existants, y compris le [...]
TME Pharma extends financial visibility by lengthening debt maturity to June 2028
26/10/2026
TME Pharma extends financial visibility by lengthening debt maturity to June 2028 Financial visibility extended to second quarter of 2028 All existing debt holders, including the CEO and two members of the Supervisory [...]
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
26/10/2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO ® — — ORPATHYS ® plus TAGRISSO ® [...]
Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
25/10/2026
Complete responses were seen in 14% of patients with head and neck squamous cell carcinoma (HNSCC) other than human papillomavirus ( HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC); 65% of responses in [...]
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
25/10/2026
Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline NANJING, China, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Nanjing [...]
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
25/10/2026
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo [...]
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
25/10/2026
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
25/10/2026
Media Release COPENHAGEN, Denmark; October 25, 2026 Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal [...]
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
25/10/2026
Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma Updated Phase 1b [...]
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
25/10/2026
44.8% ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN [...]
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
25/10/2026
Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum